Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Sponsor
Amy C. Degnim
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04570956
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
Intervention
Placebo, Questionnaire Administration, Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
Condition
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Investigators
Amy Degnim, MD, Lisa Seymour, B.S, Zachary Feldman, Seema Khan, M.D., Jess Fischer, Catherine Loveland-Jones, M.D.

See list of participating sites